Tryptamine Therapeutics Management
Management criteria checks 1/4
Tryptamine Therapeutics' CEO is Jason Carroll, appointed in Oct 2023, has a tenure of 1.17 years. total yearly compensation is A$1.39M, comprised of 16.6% salary and 83.4% bonuses, including company stock and options. directly owns 2.92% of the company’s shares, worth A$1.42M. The average tenure of the management team and the board of directors is 2 years and 1.5 years respectively.
Key information
Jason Carroll
Chief executive officer
AU$1.4m
Total compensation
| CEO salary percentage | 16.6% |
| CEO tenure | 1.2yrs |
| CEO ownership | 2.9% |
| Management average tenure | 2yrs |
| Board average tenure | 1.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$1m | AU$230k | -AU$7m |
Compensation vs Market: Jason's total compensation ($USD882.17K) is above average for companies of similar size in the Australian market ($USD295.93K).
Compensation vs Earnings: Insufficient data to compare Jason's compensation with company performance.
CEO
Jason Carroll
1.2yrs
Tenure
AU$1,390,655
Compensation
Mr. Jason Carroll serves as Chief Executive Officer of Tryptamine Therapeutics Inc. since October 01, 2023 and serves as its Managing Director since 2024 and has been its Executive Director since May 01, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | 1.2yrs | AU$1.39m | 2.92% A$ 1.4m | |
| President & Chief Scientific Officer | 4.1yrs | AU$483.96k | no data | |
| Founder & MD | no data | AU$62.79k | 15.58% A$ 7.6m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Medical Officer | 2yrs | no data | no data | |
| Company Secretary | 3.3yrs | no data | no data |
2.0yrs
Average Tenure
65yo
Average Age
Experienced Management: TYP's management team is considered experienced (2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Executive Director | less than a year | AU$1.39m | 2.92% A$ 1.4m | |
| Member of Scientific Advisory Board | 3.9yrs | no data | no data | |
| Independent Non-Executive Director | 4.3yrs | AU$37.98k | 0.13% A$ 63.7k | |
| Non-Executive Director | less than a year | no data | 0.94% A$ 456.0k | |
| Independent Non Executive Director | less than a year | AU$42.25k | 0.49% A$ 237.5k | |
| Independent Non-Executive Chairman | 1.5yrs | AU$15.00k | 0.16% A$ 76.0k | |
| Member of Scientific Advisory Board | 3.4yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.8yrs | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
1.5yrs
Average Tenure
64yo
Average Age
Experienced Board: TYP's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/17 04:17 |
| End of Day Share Price | 2024/12/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tryptamine Therapeutics Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Higgins | Ladenburg Thalmann & Company |